-
BioVaxys' preliminary toxicity study before starting application
Time of Update: 2021-11-05
Recently released clinical studies1,2 have confirmed that the use of the delayed hypersensitivity (DTH) skin test behind CoviDTH is a feasible and safe in vivo method for evaluating natural and vaccinated individuals exposed to the new coronavirus.
-
It’s all about delivery-antibodies improve nanoparticle delivery of therapeutic nucleic acids
Time of Update: 2021-11-05
Image: Antibody-guided Nanoparticle Delivery SystemSource: Baylor College of MedicineStudies have shown that some nucleic acids, such as messenger RNA (mRNA), DNA and related molecules, can effectively treat diseases in a laboratory environment.
-
Vaccines can deal with most of the new coronavirus variants
Time of Update: 2021-11-05
According to the researchers, this result shows that the vaccines of Modena and Pfizer/New Biotech have indeed enhanced the human immune system's response to infection .
-
"Nature" study reveals the mechanism of glycoprotein hormone action
Time of Update: 2021-11-05
Recently, researcher Xu Huaqiang, researcher Jiang Yi, and researcher Zhang Yan of Zhejiang University, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, jointly published research papers in the top academic journal "Nature", revealing the structural basis and molecular mechanism of the interaction between glycoprotein hormones and receptors .
-
Are some parts of your body too sensitive?
Time of Update: 2021-11-05
▲When the glabrous area (adult) is touched, the neuron signals in certain brain areas will be stronger, which is in sharp contrast with the hairy area (picture source: reference [2])But the brainstem will also be eccentric, and brainstem neurons will have a stronger connection with sensory neurons in the hairless area, amplifying the signs of sensitive skin .
-
New mechanism of perirenal fat to promote cancer revealed
Time of Update: 2021-11-05
According to reports, in clinical practice, Wang Linhui's team has observed that the kidney cancer population tends to be younger and obese, and the mechanism of action of adipose tissue, especially perrenal fat, in the occurrence and development of kidney cancer is still unclear .
-
Hong Kong University of Science and Technology found that the increase in the number of diatoms in the Pearl River estuary waters paves the way for future research on the impact of red tides/algae blooms
Time of Update: 2021-11-05
However, Liu Hongbin, the deputy director and chair professor of the Department of Marine Sciences of the University of Science and Technology who led the research, pointed out that because the team found that temperature and the nutritional content of seawater also affect the number of algae, the increase in the number of diatoms does not necessarily represent the water quality of the Pearl River Estuary.
-
New crown vaccination can reduce the risk of severe illness and death by 90%
Time of Update: 2021-11-05
According to French media reports, a large-scale study involving about 22 million people showed that vaccination of the new crown vaccine can reduce the risk of hospitalization and death by 90% for people over 50 years old, and the vaccine is also effective against Delta variants .
-
AstraZeneca's long-acting antibody cocktail therapy has positive results in the treatment of COVID-19 Phase III
Time of Update: 2021-11-05
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn October 11, AstraZeneca announced that the long-acting antibody (LAAB) cocktail therapy AZD7442 has achieved positive and high-level results in the Phase III TACKLE trial for the treatment of COVID-19 .
-
Austria adopts mouthwash test method to fight new coronavirus
Time of Update: 2021-11-05
Vienna, September 28, 2021/PRNewswire/ - Compared with other European cities, Vienna has performed better in responding to the global new crown epidemic - thanks to the PCR test specially developed by the Austrian company LEAD Horizon, which is currently the test It has been used in 13 countries .
-
Pfizer's JAK1 inhibitor receives EU CHMP support and is expected to be approved this year for the treatment of atopic dermatitis
Time of Update: 2021-11-05
Abrocitinib is a once-daily oral Janus kinase 1 (JAK1) inhibitor for adult patients with moderate/severe atopic dermatitis (AD) suitable for systemic treatment .
Reference materials:[1] Pfizer's Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis.
-
Treatment significantly prolongs the lives of patients with liver cancer, dual immunocombination therapy reaches the phase 3 clinical endpoint
Time of Update: 2021-11-05
On October 16, AstraZeneca announced that its anti-PD-L1 antibody Imfinzi, in combination with the research anti-CTLA-4 antibody tremelimumab, is in a phase 3 clinical trial for the first-line treatment of patients with unresectable hepatocellular carcinoma Reach the primary endpoint of overall survival .
-
The pan-cancer methylation product jointly developed by Benchmark Medical and Twist Bioscience is launched globally
Time of Update: 2021-11-05
This methylated pan-cancer detection product is a technical achievement jointly developed by Benchmark Medical and Twist in the past two years.
-
Using custom AAV capsids to improve drug delivery ophthalmic gene therapy Phase 1 trial results are positive
Time of Update: 2021-11-05
On October 10, 2021, 4D Molecular Therapeutics (4DMT) announced that its intravitreal injection of gene therapy 4D-125 has achieved a positive mid-term in a phase 1/2 clinical trial for patients with advanced X-linked retinitis pigmentosa (XLRP) Safety and clinical activity data .
-
Pufang Biotech announced that it will showcase its new drug linker technology aimed at expanding the therapeutic window of antibody-conjugated drugs (ADC) at the 33rd International Conference on Molecular Targets and Cancer Therapy
Time of Update: 2021-11-05
Based on the innovative technology platform, Pufang Bio has developed a series of product pipelines composed of drug candidates targeting solid tumor targets.
-
oHCM innovative medicine!
Time of Update: 2021-11-05
Bristol-Myers Squibb (BMS) recently announced that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for mavacamten, a new, oral, myosin allosteric modulator for the treatment of obstruction Hypertrophic cardiomyopathy (oHCM), which is a chronic heart disease with a high incidence .
-
Patients with rectal cancer are expected to no longer have anal canals after surgery
Time of Update: 2021-11-05
The co-completed multi-center research result "a clinical randomized controlled study on the prevention of anastomotic leakage after laparoscopic low anterior resection of rectal cancer via anal drainage tube" was published in the Journal of the American Medical Association Surgery .
-
Nat Med: Scientists clarify the mysterious link between obesity and type 2 diabetes
Time of Update: 2021-11-05
As we all know, obesity affects the body's insulin production, and over time will increase the body's risk of type 2 diabetes and a variety of other metabolic diseases; recently, an article was publis
-
100% prevention of lung cancer in mice
Time of Update: 2021-11-05
This method reassembles the whole cell components of cancer cells or tumor tissues into a nano-scale vaccine through PLGA nanoparticles, which is used for the prevention and immunotherapy of various types of cancer .
-
New Drug Delivery Technology: Combination of Supramolecular Solvent and Microemulsion
Time of Update: 2021-11-05
This difference should be due to the good compatibility of ILs as the water phase or carrier in MME with IPM, Span-20 and Tween-80, allowing medicated MEs to enter the cell membrane for drug delivery .
